title: Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases.
abstract: SPARC (secretory protein acidic and rich in cysteine), also known as osteonectin or BM-40, associates with progression in various kinds of tumors. We have examined whether SPARC expression can be a prognostic marker for patients with head and neck squamous cell carcinomas (HN-SCC). We examined immunolocalization of SPARC in 86 clinical specimens of tongue carcinoma. Although there was no correlation between SPARC positivity in the tumor cells and tumor stages, the 5-year overall survival rate was significantly lower in the SPARC positive cases (28.6%) than in the SPARC negative cases (91.7%), confined to stage II patients (p < 0.001, Wilcoxon test). Additionally, in stage II cases (n = 3), frequency of the postoperative metastasis was significantly higher in SPARC positive cases (5/8, 62.5%) than in the negative cases (1/15, 6.7%) (p < 0.01, chi2 test). Together with these results, SPARC can be a beneficial prognostic marker for the stage II tongue carcinoma, of which clinical outcomes are sometimes difficult to predict.
authors: Department of Biology and Function in the Head and Neck, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
authors: Yasumasa
authors: Y
authors: Kato
authors: Yoji
authors: Y
authors: Nagashima
authors: Yuh
authors: Y
authors: Baba
authors: Toshiro
authors: T
authors: Kawano
authors: Madoka
authors: M
authors: Furukawa
authors: Akira
authors: A
authors: Kubota
authors: Shunsuke
authors: S
authors: Yanoma
authors: Yukari
authors: Y
authors: Imagawa-Ishiguro
authors: Kenichi
authors: K
authors: Satake
authors: Takahide
authors: T
authors: Taguchi
authors: Ryu-Ichiro
authors: R
authors: Hata
authors: Izumi
authors: I
authors: Mochimatsu
authors: Ichiro
authors: I
authors: Aoki
authors: Yoichi
authors: Y
authors: Kameda
authors: Yoshiaki
authors: Y
authors: Inayama
authors: Mamoru
authors: M
authors: Tsukuda
mesh_terms: D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015676:Osteonectin / Q000096:biosynthesis*; D011379:Prognosis; D016019:Survival Analysis; D014062:Tongue Neoplasms / Q000378:metabolism / Q000473:pathology*
chemical_list: D015676:Osteonectin